Regulatory immunotoxicology: Does the published evidence support mandatory nonclinical immune function screening in drug development?

Regulatory Toxicology and Pharmacology

Volumn 40, Issue 3, 2004, Pages 336-355

  Snodin, David J ^a  

^a PAREXEL INTERNATIONAL   (United States)

Author keywords

EU; FDA: guidelines; ICH; Immune function tests; Immunostimulation; Immunosuppression; Opioids; Salmeterol

Indexed keywords

2,4 DIAMINOTOLUENE; 2,4,5 TRICHLOROPHENOXYACETIC ACID; 4 NITROTOLUENE; ALPHA INTERFERON; AMOXICILLIN; AZATHIOPRINE; BIS(TRIBUTYLTIN) OXIDE; BUPRENORPHINE; CIMETIDINE; CYCLOSPORIN A; DEXAMETHASONE; DIDANOSINE; FUROSEMIDE; INDOMETACIN; LITHIUM CARBONATE; METHADONE; MORPHINE; OPIATE; OXYMETHOLONE; PENTACHLOROPHENOL; PROCAINAMIDE; RIBAVIRIN; SALMETEROL; TETRAETHYLLEAD; TRAMADOL;

ARTICLE; ASSAY; DRUG HYPERSENSITIVITY; EUROPEAN UNION; GOVERNMENT; HUMAN; IMMUNE FUNCTION TEST; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; LIVER TOXICITY; MORBIDITY; NATURAL KILLER CELL; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELIABILITY; RODENT; TOXICITY TESTING;

2,4,5-TRICHLOROPHENOXYACETIC ACID; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ALLERGY AND IMMUNOLOGY; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EUROPEAN UNION; GUIDELINES; HERBICIDES; HUMANS; IMMUNITY; NARCOTICS; RATS; TOXICOLOGY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

RODENTIA;

EID: 8844221352     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yrtph.2004.08.007     Document Type: Article

References (113)

1. E.J. Beddowes, S.P. Faux, and J.K. Chipman Chloroform, carbon tetrachloride and glutathione depletion induce secondary genotoxicity in liver cells via oxidative stress Toxicology 187 2003 101 115
2. W.S. Beck, H.T. Scheider, K. Dietzel, B. Nuernberg, and K. Brune Gastrointestinal ulceration induced by anti-inflammatory drugs in rats. Physiological and biochemical factors involved Arch. Toxicol. 64 1990 210 217
3. L.S. Birnbaum The mechanism of dioxin toxicity: relationship to risk assessment Environ. Health Perspect. 102 Suppl 9 1994 157 167
4. L.A. Burns, S.G. Bradley, K.L. White, J.A. McCay, B.A. Fuchs, M. Stern, R.D. Brown, D.L. Musgrove, M.P. Holsapple, and M.I. Luster Immunotoxicity of 2,4-diaminotoluene in female B6C3F1 mice Drug Chem. Toxicol. 17 1994 401 436
5. L.A. Burns, S.G. Bradley, K.L. White, J.A. McCay, B.A. Fuchs, M. Stern, R.D. Brown, D.L. Musgrove, M.P. Holsapple, and M.I. Luster Immunotoxicity of mono-nitrotoluenes in female B6C3F1 mice I. Para-nitrotoluene Drug Chem. Toxicol. 17 1994 317 358
6. L.A. Burns, S.G. Bradley, K.L. White, J.A. McCay, B.A. Fuchs, M. Stern, R.D. Brown, D.L. Musgrove, M.P. Holsapple, and M.I. Luster Immunotoxicity of nitrobenzene in female B6C3F1 mice Drug Chem. Toxicol. 17 1994 271 315
7. P.J. Butler, L.E. Randle, R. Jones, P. Macrae, J. Blagg, D.A. Smith, D.P. Williams, and K. Park The role of metabolism in furosemide toxicity BTS Newsletter 24 2004 35
8. M.C. Carakostas Interpreting clinical laboratory data in safety assessment studies Toxicol. Pathol. 20 1992 480 483
9. M.C. Carakostas, and A.K. Banerjee Interpreting rodent clinical laboratory data in safety assessment studies: biological and analytical components of variation Fundam. Appl. Toxicol. 15 1990 744 753
10. I. Cavero, M. Mestre, J.M. Guillon, and W. Crumb Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias Expert Opin. Pharmacother. 1 2000 947 973
11. M. Cazzola, R. Testi, and M.G. Matera Clinical pharmacokinetics of salmeterol Clin. Pharmacokinet. 41 2002 19 30
12. K. Cederbrant, M. Marcusson-Stahl, F. Condevaux, and J. Descotes NK-cell activity in immunotoxicity drug evaluation Toxicology 185 2003 241 250
13. CDER (Center for Drug Evaluation and Research) 2002. Immunotoxicology evaluation of investigational new drugs. US Department of Health and Human Services, Food and Drug Administration
14. Q.Y. Chen, J.Q. Yang, and C.M. Mi Effect of ribavirin on NK activities of murine spleen cells in vitro Yao Xue Xue Bao 30 1995 417 421
15. P. Chervinsky, P. Goldberg, S. Galant, Y. Wang, T. Arledge, M.B. Welch, and E. Stahl Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomised clinical trial Chest 115 1999 642 648
16. CHMP., 2004. CHMP SWP conclusions and recommendations on the use of genetically modified animal models for carcinogenicity assessment. Available from: 〈 http://www.emea.eu.int/pdfs/human/swp/259202en.pdf 〉
17. S.M. Cohen, D. Robinson, and J. MacDonald Alternative models for carcinogenicity testing Toxicol. Sci. 64 2001 14 19
18. F. Condevaux, J. Guichard, A. Forichon, M. Aujoulat, and J. Descotes Compared effects of morphine and nickel chloride on NK cell activity in vitro in rats and monkeys J. Appl. Toxicol. 21 2001 431 434
19. CPMP-Committee on Proprietary Medicinal Products. 2000. Note for guidance on repeated-dose toxicity. CPMP/SWP/1042/99
20. J.H. Dean, and B. Remandet Integration of immunotoxicology evaluation in drug development Drug Inf. J. 31 1997 1347 1356
21. J.H. Dean, J.R. Hinks, and B. Remandet Immunotoxicology assessment in the pharmaceutical industry Toxicol. Lett. 102-103 1998 247 255
22. J.H. Dean, R.V. House, and M.I. Luster Immunotoxicology: effects of, and response to, drugs and chemicals A. Hayes Wallace Principles and Methods of Toxicology 2001 Taylor & Francis Philadelphia 1415 1450
23. J.H. Dean A brief history of immunotoxicology and a review of the pharmaceutical guidelines Int. J. Toxicol. 23 2004 83 90
24. F. De Clerck, A. Van de Water, J. D'Aubioul, H.R. Lu, K. van Rossem, A. Hermans, and K. Van Ammel In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity Fundam. Clin. Pharmacol. 16 2002 125 140
25. J. Descotes Immunotoxicity of pharmaceuticals: an introduction Drug Inf. J. 30 1996 271 274
26. J. Descotes Importance of immunotoxicity in safety assessment: a medical toxicologist's perspective Toxicol. Lett. 149 2004 103 108
27. J. Descotes, B. Nicolas, and T. Vial Assessment of immunotoxic effects in humans Clin. Chem. 41 1995 1870 1873
28. J. Descotes, G. Choquet-Kastylevsky, E. Van Ganse, and T. Vial Responses of the immune system to injury Toxicol. Pathol. 28 2000 479 481
29. G. Descotes, D. Pinard, J.F. Gallas, E. Penacchio, C. Blot, and C. Moreau Extension of the 4-week safety study for detecting immune system impairment appears not necessary: example of cyclosporin A in rats Toxicology 112 1996 245 256
30. W.H. De Jong, E.D. Kroese, J.G. Vos, and H. van Loveren Detection of immunotoxicity of benzo[a]pyrene in a subacute toxicity study after oral exposure in rats Toxicol. Sci. 50 1999 214 220
31. E.J. De Waal, H.H. Timmerman, P.M. Dortant, M.A. Kranjc, and H. van Loveren Investigation of a screening battery for immunotoxicity of pharmaceuticals within a 28-day oral toxicity study using azathioprine and cyclosporin A as model compounds Regul. Toxicol. Pharmacol. 21 1995 327 338
32. E.J. De Waal, J.W. van der Laan, and H. van Loveren Immunotoxicity of pharmaceuticals: a regulatory perspective TEN 3 1996 165 172
33. E.J. De Waal, W.H. de Jong, H. van der Vliet, B. Verlaan, and H. van Loveren An immunotoxicity screening study on salmeterol in rats Int. J. Immunopharmacol. 18 1996 523 528
34. E.J. De Waal, H. van Loveren, and J.G. Vos Practice of tiered testing for immunosuppression in rodents Drug Inf. J. 31 1997 1317 1323
35. E.J. De Waal, J.W. van der Laan, and H. van Loveren Effects of prolonged exposure to morphine and methadone on in vivo parameters of immune function in rats Toxicology 129 1998 201 210
36. E.J. De Waal, W.H. de Jong, A.J. van der Stappen, B. Verlaan, and H. van Loveren Effects of salmeterol on host resistance to Trichinella spiralis in rats Int. J. Immunopharmacol. 21 1999 523 529
37. R.M. Donahoe, L.D. Byrd, H.M. McClure, M. Brantley, D. Wenzel, A.A. Ansari, and F. Marsteller Effects of morphine on T-cell recirculation in rhesus monkeys Adv. Exp. Med. Biol. 493 2001 89 101
38. R.B. Dowling, M. Johnson, P.J. Cole, and R. Wilson Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro Eur. Respir. J. 11 1998 86 90
39. D.C. Evans, A.P. Watt, D.A. Nicoll-Griffith, and T.A. Baillie Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development Chem. Res. Toxicol. 17 2004 3 16
40. Ezendam, J., Hassing, I., Bleumink, R., Vos, J.G., Pieters, R., 2003. Hexachlorobenzene-induced immunopathology in brown Norway rats is partly mediated by T cells. Toxicol. Sci. December 2, advance publication.
41. B. Fermini, and A.A. Fossa The impact of drug-induced QT interval prolongation on drug discovery and development Nat. Rev. Drug Discov. 2 2003 439 447
42. G.T. Ferguson, C. Funck-Brentano, T. Fischer, P. Darken, and C. Reisner Cardiovascular safety of salmeterol in COPD Chest 123 2003 1817 1824
43. L.R. Flores, S.M. Wahl, and B.M. Bayer Mechanism of morphine-induced immunosuppression: effect of acute morphine administration on lymphocyte tracking J. Pharmacol. Exp. Ther. 272 1995 1246 1251
44. D.H. Garabrant, and M.A. Philbert Review of 2,4-dichlorophenoxyacetic acid (2,4-D) epidemiology and toxicology Crit. Rev. Toxicol. 32 2002 233 257
45. L. Gaspani, M. Bianchi, E. Limiroli, A.E. Panerai, and P. Sacerdote The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats J. Neuroimmunol. 129 2002 18 24
46. D.R. Germolec, A. Nyska, M. Kashon, C.F. Kuper, C. Portier, C. Kommineni, K.A. Johnson, and M.I. Luster Extended histopathology in immunotoxicity testing: interlaboratory validation studies Toxicol. Sci. 78 2004 107 115
47. Hardman, J.G., Limbird, L.E. (Eds.), 2001. Goodman and Gilman's The Pharmacological Basis of Therapeutics, tenth ed. McGraw Hill, New York
48. T.L. Guo, J.A. McCay, R.D. Brown, D.L. Musgrove, D.R. Germolec, L. Butterworth, A.E. Munson, and K.L. White Jr. Carbon tetrachloride is immunosuppressive and decreases host resistance in Listeria monocytogenes and Streptococcus pneumoniae in female B6C3F1 mice Toxicology 154 2000 85 101
49. Haley, P.J. (2002). Guidelines on immunotoxicity testing of new chemical entities; consideration of a conundrum. Regulatory and Safety Evaluation Speciality Section Newsletter of the Society of Toxicology. Fall 2002, 3-5
50. P.J. Haley Species differences in the structure and function of the immune system Toxicology 188 2003 49 71
51. K.L. Hastings, C.-H. Ahn, S.Y. Alam, A. Aszalos, Y.S. Choi, J.J. Jessop, and J.L. Weaver Considerations in assessing the immunotoxic potential of investigational drugs Drug Inf. J. 31 1997 1357 1361
52. K.L. Hastings Implications of the new FDA/CDER immunotoxicology guidance for drugs Int. Immunpharmacol. 2 2002 1613 1618
53. M.C. Hernandez, L.R. Flores, and B.M. Bayer Immunosuppression by morphine is mediated by central pathways J. Pharmacol. Exp. Ther. 267 1993 1336 1342
54. D.J. Herzyk, and E.R. Gore Adequate immunotoxicity testing in drug development Toxicol. Lett. 149 2004 115 122
55. C.R. Kirman, L.M. Sweeney, M.E. Meek, and M.L. Gargas Assessing dose dependency of allometric scaling performance using physiologically based pharmacokinetic modelling Regul. Toxicol. Pharmacol. 38 2003 345 367
56. S.H. Huang, A.F. Hubbs, C.F. Stanley, V. Vallyathan, P.C. Schnabel, Y. Rojanasakul, J.K. Ma, D.E. Banks, and D.N. Weissman Immunoglobulin responses to experimental silicosis Toxicol. Sci. 59 2001 108 117
57. Immunotoxicology Technical Committee, International Life Sciences Institute Health and Environmental Sciences Institute. 2001. Application of flow cytometry to immunotoxicity: summary of a workshop. Toxicology. 163, 39-48
58. L. Institoris, O. Siroki, I. Desi, J. Lesznyak, P. Serenyi, E. Szekeres, and I. Petri Extension of the protocol of OECD guideline 407 (28-day repeated dose oral toxicity test in the rat) to detect potential immunotoxicity of chemicals Hum. Exp. Toxicol. 17 1998 206 211
59. H. Jaeschke, G.J. Gores, A.I. Cederbaum, J.A. Hinson, D. Pessayre, and J.J. Lemasters Mechanisms of hepatotoxicity Toxicol. Sci. 65 2002 166 176
60. C. Ju, and J.P. Uetrecht Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system Curr. Drug Metab. 3 2002 367 377
61. I. Kimber, and R.J. Dearman Immune responses: adverse versus non-adverse effects Toxicol. Pathol. 30 2002 54 58
62. S.R. Knowles, J. Uetrecht, and N.H. Shear Idiosyncratic drug reactions: the reactive metabolite syndromes Lancet 356 2000 1587 1591
63. G.S. Ladics, C. Smith, G.S. Elliott, T.W. Slone, and S.E. Loveless Further evaluation of the incorporation of an immunotoxicological functional assay for assessing humoral immunity for hazard identification purposes in rats in a standard toxicology study Toxicology 126 1998 137 152
64. H. Lebrec, C. Blot, S. Pequet, R. Roger, C. Bohuon, and M. Pallardy Immunotoxicological investigation using pharmaceutical drugs: in vivo evaluation of immune effects Fundam. Appl. Toxicol. 23 1994 159 168
65. D.G. LeVier, J.A. McCay, M.L. Stern, L.S. Harris, D. Page, R.D. Brown, D.L. Musgrove, L.F. Butterworth, K.L. White Jr., and A.E. Munson Immunological profile of morphine sulphate in B6C3F1 female mice Fundam. Appl. Toxicol. 22 1994 525 542
66. D.G. LeVier, R.D. Brown, D.L. Musgrove, L.F. Butterworth, J.A. McCay, K.L. White Jr., B.A. Fuchs, L.S. Harris, and A.E. Munson The effect of methadone on the immune status of B6C3F1 mice Fundam. Appl. Toxicol. 22 1995 275 284
67. R.W. Lewis, R. Billington, E. Debryune, A. Gamer, G. Lang, and F. Carpanini Recognition of adverse and nonadverse effects in toxicity studies Toxicol. Pathol. 30 2002 66 74
68. M.I. Luster, C. Portier, D.G. Pait, L.K. White Jr., C. Gennings, A.E. Munson, and G.J. Rosenthal Risk assessment in immunotoxicology. I Sensitivity and predictability of immune tests Fundam. Appl. Toxicol. 18 1992 200 210
69. M.I. Luster, and G.J. Rosenthal Chemical agents and the immune response Environ. Health Perspect. 100 1993 219 226
70. M.I. Luster, C. Portier, D.G. Pait, G.J. Rosenthal, D.R. Germolec, E. Corsini, B.L. Blaylock, P. Pollock, Y. Louchi, W. Craig, K.L. White, A.E. Munson, and C.E. Comment Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests Fundam. Appl. Toxicol. 21 1993 71 82
71. G.R. Manchee, A. Barrow, S. Kulkarni, E. Palmer, J. Oxford, P.V. Colthup, J.G. Maconochie, and M.H. Tarbit Disposition of salmeterol xinafoate in laboratory animals and humans Drug Metab. Dispos. 21 1993 1022 1028
72. J.L. Masferrer, A. Koki, and K. Siebert COX-2 inhibitors. A new class of antiangiogenic drugs Ann. NY Acad. Sci. 889 1999 84 86
73. T.E. Massey, R.M. Walker, T.F. McElligott, and W.J. Racz Furosemide toxicity in isolated mouse suspensions Toxicology 43 1987 149 160
74. K. Matsumoto, K. Sekita, T. Ochiai, A. Takagi, K. Takada, T. Furuya, Y. Kurokawa, Y. Saito, R. Teshima, and K. Suziki Evaluation of immunotoxicity testings using azathioprine-treated rats: the International Collaborative Immunotoxicity Study Azathioprine Eisei Shikenjo Hokoku 108 1990 34 39
75. C. Michielsen, N. Bloksma, A. Ultee, F. van Mil, and J.G. Vos Hexaclorobenzene-induced immunomodulation and skin an lung lesions: a comparison between brown Norway, Lewis and Wistar rats Toxicol. Appl. Pharmacol. 144 1977 12 26
76. C. Michielsen, H. van Loveren, and J.G. Vos The role of the immune system in hexachlorobenzene-induced toxicity Environ. Health Perspect. 107 Suppl. 5 1999 783 792
77. J.R. Mitchell, W.R. Snodgrass, and J.R. Gillette The role of biotransformation in chemical-induced liver injury Environ. Health Perspect. 15 1976 27 38
78. J.R. Mitchell, W.L. Nelson, W.Z. Potter, H.A. Sasame, and D.J. Jollow Metabolic activation of furosemide to a chemically reactive, hepatotoxic metabolite J. Pharmacol. Exp. Ther. 199 1976 41 52
79. I.D. Mitchell, R.W. Rees, P.J. Gilbert, and J.B. Carlton The use of historical data for identifying biologically unimportant but statistically significant results in genotoxicity assays Mutagenesis 5 1990 159 164
80. I.C. Munro, G.L. Carlo, J.C. Orr, K.G. Sund, R.M. Wilson, E. Kennepohl, B.S. Lynch, M. Jablinske, and N.L. Lee A comprehensive, integrated review and evaluation of the scientific evidence relating to the safety of the herbicide 2,4-D J. Am. Coll. Toxicol. 11 1992 559 664
81. A.L. Muzikant, and R.C. Penland Models for profiling the potential QT prolongation risk of drugs Curr. Opin. Drug Discov. Dev. 5 2002 127 135
82. M. Pallardy, C. Blot, S. Kerdine, H. Lebrec, R. Roger, and P. Rieu Evaluation of the immunotoxic potential of pharmaceuticals: functional aspects Drug Inf. J. 31 1997 1331 1336
83. B.K. Park, N.R. Kitteringham, H. Powell, and M. Pirmohamed Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity Toxicology 153 2000 39 60
84. B.K. Park, D.J. Naisbitt, S.F. Gordon, N.R. Kitteringham, and M. Pirmohamed Metabolic activation in drug allergies Toxicology 158 2001 11 23
85. K.E. Phillips, J.A. McCay, R.D. Brown, D.L. Musgrove, B.J. Meade, L.F. Butterworth, S. Wilson, K.L White Jr., and A.E. Munson Immunotoxicity of 2′,3′-dideoxyinosine in female B6C3F1 mice Drug Chem. Toxicol. 20 1997 189 228
86. K.E. Phillips, and A.E. Munson 2′,3′-Dideoxyinosine inhibits the humoral response in female B6C3F1 mice by targeting the B lymphocyte Toxicol. Appl. Pharmacol. 145 1997 260 267
87. M.D. Phillips, B. Nascimbeni, R.R. Tice, and M.D. Shelby Induction of micronuclei in mouse bone marrow cells: an evaluation of nucleoside analogues used in the treatment of AIDS Environ. Mol. Mutagen. 18 1991 168 183
88. W.J. Pichler Predictive drug allergy testing: an alternative viewpoint Toxicology 158 2001 31 41
89. S.B. Pruett, D.K. Ensley, and P.L. Crittenden The role of chemical-induced stress responses in immunosuppression: A review of quantitative associations and cause-effect relationships between chemical-induced stress responses and immunosuppression J. Toxicol. Environ. Health 39 1993 163 192
90. E. Putman, J.W. vander Laan, and H. van Loveren Assessing immunotoxicity: guidelines Fundam. Clin. Pharmacol. 17 2003 615 626
91. E. Putman, H. van Loveren, G. Bode, J. Dean, K. Hastings, K. Nakamura, F. Verdier, and J.W. van derLaan Assessment of the immunotoxic potential of human pharmaceuticals: a workshop report Drug Inf. J. 36 2002 417 427
92. K.F. Rabe State of the art in beta2-agonist therapy: a safety review of long-acting agents Int. J. Clin. Pract. 57 2003 689 697
93. W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. MacKenzie, S. Palethorpe, P.K. Siegl, I. Strang, A.T. Sullivan, R. Wallis, A.J. Camm, and T.G. Hammond Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardivasc. Res. 58 2003 32 45
94. H.-B. Richter-Reichhelm, and A.E. Schulte Results of a cyclosporin A ringstudy Toxicology 129 1998 91 94
95. P. Sacerdote, M. Bianchi, B. Manfredi, and A.E. Panerai Effects of tramadol on immune responses and nociceptive thresholds in mice Pain 72 1997 325 330
96. P. Schielen, C. den Besten, J.G. Vos, P.J. van Bladderen, W. Seinen, and N. Bloksma Immune effects of hexachlorobenzene in the rat: role of metabolism in a 13-week feeding study Toxicol. Appl. Pharmacol. 131 1995 37 43
97. A. Schulte, J. Althoff, S. Ewe, and H-B. Richter-Reichhelm Two immunotoxicity ring studies according to OECD TG 407 comparison of data on cyclosporin A and hexachlorobenzene Regul. Toxicol. Pharmacol. 36 2002 12 21
98. R.J. Smialowicz Immune function testing for the identification and characterisation of immunotoxicity in rodents Hum. Exp. Toxicol. 14 1995 135 136
99. C.K. Svensson, E.W. Cowen, and A.A. Gaspari Cutaneous drug reactions Pharmacol. Rev. 53 2001 357 379
100. N. Talal, and H. Dang Drug-induced autoimmunity and autoimmune disease Drug Inf. J. 31 1997 1307 1309
101. J.W. Van der Laan, E.I. Krajnc, M.A.M. Krajnc-Franken, and H. van Loveren Immunological screening test of morphine and methadone in an extended 28-day study in rats Int. J. Immunopharmacol. 17 1995 535 543
102. J.W. Van der Laan, H. Timmerman, and H. van Loveren Comparison of the in vivo effects of morphine and methadone on natural killer cell activity in spleen, peritoneal cavity, and lungs in rats Int. J. Immunopharmacol. 18 1996 401 407
103. J.W. Van der Laan, H. van Loveren, J.G. Vos, J.H. Dean, and K.L. Hastings Immunotoxicity of pharmaceuticals: current knowledge, testing strategies, risk evaluation and consequences for human health Drug Inf. J. 31 1997 1301 1305
104. H. Van Loveren Host resistance models Hum. Exp. Toxicol. 14 1995 137 140
105. H. Van Loveren, N. Gianotten, C.F.M. Hendriksen, H.J. Schuurman, and J.W. van der Laan Assessment of immunotoxicity of buprenorphine Lab. Anim. 28 1994 355 363
106. H. Van Loveren, P.A. Steerenberg, and J.G. Vos Early detection of immunotoxicity: from animals to human biomonitoring Toxicol. Lett. 77 1995 73 80
107. H. Van Loveren, R.W. Luebke, and J.G. Vos Assessment of immunotoxicity with the parasitic infection model Trichinella spiralis G.R. Burleson J.H. Dean A.E. Munson Methods in Immunotoxicology vol. 2 1995 Wiley-Liss New York 243 271
108. H. Van Loveren, J.G. Vos, and E.J. de Waal Testing immunotoxicity of chemicals as a guide for testing approaches for pharmaceuticals Drug Inf. J. 30 1996 275 279
109. T. Vial, G. Choquet-Kastylevsky, and J. Descotes Adverse effects of immunotherapeutics involving the immune system Toxicology 174 2002 3 11
110. J.G. Vos, A. de Klerk, E.I. Krajnc, H. van Loveren, and J. Rozing Immunotoxicity of bis(tri-n-butyltin)oxide in the rat: effects on thymus-dependent immunity and on non-specific resistance following long-term exposure in young versus aged rats Toxicol. Appl. Pharmacol. 105 1990 144 155
111. J.G. Vos, and H. van Loveren Experimental studies on immunosuppression: how do they predict for man? Toxicology 129 1998 13 26
112. R.M. Walker, and T.F. McElligott Furosemide induced hepatotoxicity J. Pathol. 135 1981 301 314
113. S.D. Wilson, J.A. McCay, L.F. Butterworth, A.E. Munson, and K.L. White Jr. Correlation of suppressed natural killer cell activity with altered host resistance models in B6C3F1 mice Toxicol. Appl. Pharmacol. 177 2001 208 218